ICE Bioscience Application Notes

Vertex Pharmaceuticals has developed an innovative pain treatment drug, VX-548, also known as suzetrigine. Targeting Nav1.8, a voltage-gated sodium channel crucial in transmitting pain signals, VX-548 demonstrates high selectivity for Nav1.8. This specificity could potentially provide superior analgesic effects compared to opioid drugs, while avoiding addiction and other side effects.

VX-548 stands to become the first new drug for treating acute and neuropathic pain in over two decades, representing a significant breakthrough in pain management. Meanwhile, the global race to develop Nav1.8 inhibitors is heating up. Chinese pharmaceutical company Hengrui Pharma is also advancing its own Nav1.8 inhibitor, showcasing China's rapid progress in this field. Vertex's extensive portfolio in pain treatment, including both Nav1.8 and Nav1.7 inhibitors, highlights its commitment and ambition to lead in this therapeutic area.

Our data indicates VX-548's potent inhibition of Nav1.8 channels, with minimal off-target effects on other sodium channels, as shown below:

These results underscore VX-548's superior selectivity and potency in human Nav1.8 channels compared to rat models, reinforcing its potential in clinical settings.

Our studies also examined the impact of VX-548 on rat dorsal root ganglion (DRG) neurons' action potentials. VX-548 effectively inhibited action potentials in rat DRG neurons, which are crucial for pain signal transmission. The concentration-dependent effects showed a significant reduction in the frequency and amplitude of action potentials at various concentrations of VX-548.